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Objective: To determine if patient self-administration of hydrocortisone will safely achieve
superior symptom control for all hydrocortisone-responding disorders as it does for
Addison’s disease and rheumatoid arthritis.
Methods: Two thousand four hundred and twenty-eight participants with hydrocortisone-
responding disorders were brought to a minimum symptom state using daily administered hydro-
cortisone tablets in a 24-week, open study. Thereafter, participants used 5-day, low-dose hydro-
cortisone regimens to quench subsequent disorder exacerbations (ﬂares) to maintain the minimum
symptom state. Stressors such as emotional traumas, infections, allergies, and injuries were mini-
mized to reduce disorder intensity, hydrocortisone consumption, and participant discomfort.
Results: Two thousand ﬁfteen participants, 601 with ﬁbromyalgia, 579 with osteoarthritis,
246 with rheumatoid arthritis, 226 with undifferentiated arthritis, 75 with back pain, 51 with
Parkinson’s disease, 44 with polymyalgia rheumatica, 25 with neuropathy, 25 with chronic
fatigue syndrome, 25 with dementia, 21 with migraine headache, 19 with multiple sclerosis,
and 78 with other disorders completed the 24-week study to achieve a composite average
symptom improvement of 76% with equal response rates. The participants averaged ingest-
ing 12 mg of hydrocortisone per day. No signiﬁcant adverse reactions were observed.
Conclusions: Patient self-administration of hydrocortisone safely achieves superior symptom
control for 38 hydrocortisone-responding disorders at equal rates and symptom improvements to
conﬁrm and amplify an earlier double-blind study ﬁnding on rheumatoid arthritis. These results
are consistent with the body having an inﬂammation control system and chronic inﬂammation
being a disorder unto itself with differing symptoms sets dependent on its location.
Clinical Trials Government Identiﬁer: NCT03558971
Keywords: general theory of inﬂammation, chronic inﬂammation, inﬂammation control
system, pain, osteoarthritis, ﬁbromyalgia
Introduction
Patient self-administration of corticosteroids, wherein dosage is matched with symptom
intensity, has proven effective to control the symptom variability of Addison’s disease
safely.
Later, patient self-administration of prednisone was proven effective to control
the symptom variability of rheumatoid arthritis safely. In a double-blind trial,
superior to standard-of-care treatment effectiveness was achieved with no signiﬁ-
cant adverse reactions.1
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A hypothesis has been proposed that hydrocortisone-
responding disorders arise from a defect in an inﬂammation
control system. The latter was deﬁned as a minor modiﬁca-
tion in the operation of the hypthalamic–pituitary–adrenal
(HPA) axis.2 When the defect occurs, short-term, beneﬁcial
inﬂammation evolves unhindered into long-term, destructive
inﬂammation. The hypothesis assumes the common denomi-
nator of hydrocortisone-responding disorders is chronic
inﬂammation and the differing symptom sets observed are
consequences of chronic inﬂammation existing in various
locations. If this hypothesis were true, all hydrocortisone-
responding disorders should respond with equal rates and
efﬁcacies to one effective chronic inﬂammation treatment.
This 24-week study is to determine if patient self-
administration of hydrocortisone performs with equal
rates and equal efﬁcacies for all hydrocortisone-
responding disorders safely.
Methods
The method of this study is that of the preceding double-
blind study on rheumatoid arthritis1 modiﬁed by adding
stress management, increasing the induction period length
and relating hydrocortisone dosages to body mass.
Two thousand four hundred and twenty-eight partici-
pants with hydrocortisone-responding disorders were con-
tinuously enrolled. Of the 2,015 participants completing the
study, 1,635 were females of average age 66 and 380 were
males of average age 67. The age range was 18–97.
Disqualifying conditions were congestive heart failure, sto-
mach ulceration, and unstable diabetes. Participants who
were using a daily corticosteroid regimen prior to the study
were maintained using the daily physiological dosage of that
corticosteroid in addition to the study protocol.
The study protocol was: week 1) qualifying medical
examination, food sensitivity laboratory test, daily moni-
toring of symptom intensities for establishing baseline;
weeks 2-4) daily ingesting hydrocortisone tablets to
achieve a minimum symptom state, monitoring symptom
intensities for daily change from baseline and hydrocorti-
sone response to dosage, laboratory-determined sensitive
foods eliminated from diets, medical examination 2 at the
end of week 4; and weeks 5-24) patient education, parti-
cipant self-administration of hydrocortisone, monitoring of
symptom intensities for daily change from baseline,
laboratory-determined sensitive foods eliminated from
diets, medical examination 3 at the end of week 24.
Hydrocortisone was administered daily for 3 weeks to
achieve a minimum symptom state. This induction period
(shower) consisted of ingesting hydrocortisone tablets at one
time daily at 7–9 amaccording to the schedule given inTable 1.
Those who failed to attain signiﬁcant symptom
improvement during the induction period were disqualiﬁed
from the study.
For those who responded to hydrocortisone adminis-
tration but failed to achieve the objective 75% symptom
improvement, the induction period was repeated with the
daily addition of adult dosage doxycycline to optimize
symptom control. The latter was continued for 30 days
beyond the end of the repeated induction period.
To maintain the minimum symptom state after the
induction period, participants were taught for what reasons
and when to ingest 5-day hydrocortisone regimens (boos-
ters) for quenching disorder ﬂares.
The 5-day ﬂare-quenching regimen consisted of ingest-
ing hydrocortisone tablets during day 1 immediately upon
ﬂare recognition and during days 2–5 at 7–9 am. The
booster hydrocortisone dosages are given in Table 2.
Stress management was necessary for some partici-
pants to achieve and maintain a satisfactory minimum
symptom state. For this study, stressors were deﬁned to
be emotional traumas, allergies, infections, and injuries.
Education principles were: restrict total hydrocortisone
available to within its safe use limit per month;4 limit
booster use to four times a month; implement boosters at
the early onset of a ﬂare; ingest hydrocortisone between 7
and 9 am except for the ﬁrst day dose of the booster that is
to be taken immediately upon ﬂare recognition; take the
daily hydrocortisone dosage at one time and do not spread
it out throughout the day; minimize emotional traumas;
restrict each participant’s diet to exclude participant-
speciﬁc, laboratory-determined sensitive foods; and mini-
mize strenuous work and exercise of inﬂamed areas.
Table 1 Hydrocortisone dosages of the induction period
Body mass Week 1 Week 2 Week 3
>68 kg 60 mg/day 40 mg/day 20 mg/day
68 to 114 kg 80 60 40
>114 kg 100 80 60
Table 2 Hydrocortisone of the 5-day ﬂare-quenching booster
Body mass Day 1 Day 2 Day 3 Day 4 Day 5
<68 kg 30 mg 20 mg 20 mg 20 mg 10 mg
150 to 250 kg 40 30 20 20 10
>114 kg 50 40 30 20 10
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If a participant experienced signiﬁcant symptom enhance-
ment during days in which no hydrocortisone was ingested,
that is, hydrocortisone holidays, an am/pm blood hydrocorti-
sone test was performed. If the homeostasis hydrocortisone
blood levels were signiﬁcantly below average, daily hydro-
cortisone supplementation was administered in addition to
patient self-administration of hydrocortisone of the study.
Short-term hydrocortisone overdosage warnings were
the appearance of a moon face and a hyper state. When
observed, patient compliance was reviewed and appropri-
ate action taken.
Eighty-one physicians from 20 states performed the
required medical examinations, provided the diagnoses, pre-
scribed the medicine, and monitored participant progress.
Outcome was determined by having participants rate each
symptom intensity that characterizes the disorder being treated
at the same time daily using a deﬁned 0–10 scale.1 The
assigned numbers for each symptom were added to give the
total score daily. The total score was plotted vs time. A second
graph line of hydrocortisone ingested vs time was superim-
posed upon the total score graph to evaluate dose-response
relationship.
Results
Two thousand four hundred and twenty-eight participants
were enrolled into the study. Four hundred and thirteen parti-
cipants were discontinued due to unsatisfactory outcome. Two
thousand ﬁfteen participants completed the study. For the
participants who completed the study, the average symptom
improvement was 76%, see Table 3. No signiﬁcant adverse
reactions were reported. Participants averaged ingesting 12mg
hydrocortisone per day. For the disorders where n is >50
excluding undifferentiated arthritis, the mean average symp-
tom improvement from baseline was 73%with a sigma of 6%.
Participants where n>245 diagnosed with ﬁbromyalgia,
osteoarthritis and rheumatoid arthritis who completed the
study achieved an overall 77% average symptom improve-
ment. The 601 participants with ﬁbromyalgia averaged
77% symptom improvement; the 579 with osteoarthritis,
77%; and the 246 with rheumatoid arthritis, 78%.
The response rate to treatment was identical for all
disorders.
Discussion
General theory of inﬂammation
The inﬂammation control system of the body2 terminates
acute inﬂammation at its due time. In normal operation, an
inﬂammation-initiating event causes acute inﬂammation to
occur which in turn activates the HPA axis to make an
approximate 12-fold, 4 hrs, hydrocortisone surge concen-
tration in the blood (surge). This surge then terminates the
very inﬂammation that activated the HPA axis in the ﬁrst
place much as an electrical switch turns off a light.
As the surge weakens with age, injury, and heredity,
acute inﬂammation evolves into chronic inﬂammation pro-
portionately while being manifested as bad days (ﬂares)
for patients.
Table 3 The average symptom improvement (efﬁcacy) of parti-
cipants arranged by decreasing number of participants (n)
Disorder n Efﬁcacy, %
Fibromyalgia 601 77
Osteoarthritis 579 77
Rheumatoid arthritis 246 78
Arthritis, undifferentiated 226 76
Back pain 75 70
Parkinson’s disease 51 62
Polymyalgia rheumatica 44 80
Chronic fatigue syndrome 25 78
Neuropathy 25 74
Dementia, Parkinson’s disease 22 67
Headache, migraine 21 86
Multiple sclerosis 19 67
Asthma 11 68
Systemic lupus erythematosis 9 60
Bursitis 6 79
Irritable bowel syndrome 6 71
Psoriatic arthritis 6 63
Crohn’s disease 5 92
Carpal tunnel syndrome 5 86
Spinal stenosis 4 78
Headache 3 84
Nervous system symptoms 3 63
Ankylosing spondylitis 3 60
Urinary tract inﬂammation 3 58
Post traumatic stress disorder 2 71
Acid reﬂux 1 100
Bowel inﬂammation 1 100
Scoliosis 1 100
Dementia, rheumatoid arthritis 1 92
Dementia 1 86
Eye inﬂammation 1 85
Eczema 1 77
Myofacial syndrome 1 73
Meniere’s disease 1 69
Sjogren’s syndrome 1 69
Dementia, multiple sclerosis 1 67
Restless leg syndrome 1 47
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Resolution of chronic inﬂammation
The solution is teaching patients to ingest hydrocortisone
tablets on the bad days and not on the good ones to manually
restore the pulse to its effective concentration in the blood. In
this way, only the missing hydrocortisone is replaced thereby
avoiding overdosing adverse effects. Patient self-
administration is mandated since only patients experience the
bad days.
Flares should be terminated during their earliest stages
to minimize hydrocortisone consumption and patient dis-
comfort since the amount of hydrocortisone required to
terminate inﬂammation is related to inﬂammation intensity.3
Patients must be brought to a minimum symptom state
before employing patient self-administration. If they were
not to do this, they would be unable to judge ﬂare occur-
rences from background symptom intensities satisfactorily.
Patients are expected to experience 3.3 ﬂares each month.1
The hydrocortisone amount in each booster is 25% of the
monthly safe use limit.4 With the restriction of using
amaximumof 4 boosters permonth, this limits hydrocortisone
use to its safe use limit. If patients were to use 3.3 boosters per
month, there would be a comfortable 17.5% margin of error.
Adrenal suppression is avoided by incorporating hydrocor-
tisone holidays. Participants using themaximum4boosters per
month would have 8–11 hydrocortisone holidays irregularly
interspersed throughout a month during which natural produc-
tion of hydrocortisone by the adrenal glands is exercised.
Participants incapable of judging early stage ﬂares used
a simpler, yet effective plan, whereby the 5-day booster
was ingested during the week days thereby leaving
Saturdays and Sundays as hydrocortisone holidays.
Inﬂammation-initiating and enhancing events, such as
emotional traumas, allergies,5 infections,6,7 and injuries,
must be minimized for optimum success. In implementation,
participants excluded laboratory-determined allergenic foods
from their diets, took a broad-spectrum antibiotic, and
avoided strenuous exercise of inﬂamed tissues. Slow hydro-
cortisone-responding participants ingested a broad-spectrum
antibiotic during the repeated induction period and for 1
month thereafter to suppress occult infections.
The 3-week induction period left 21 weeks of this 24-week
study to learn if patients were capable of maintaining the
minimum symptom state using patient self-administration of
hydrocortisone. Patients were expected to average 17.3 ﬂares
during the 21 weeks at the rate of 3.3 ﬂares per month. This
number of ﬂares was judged adequate for judging patient
capability.
Educators contacted the participants weekly to monitor
compliance, total score improvement from baseline,
adverse effect occurrence, and train and retrain as needed.
Educators contacted the attending physicians monthly to
solicit adverse event occurrence data and provide them
with participant compliance, hydrocortisone consumption,
and symptom improvement from baseline data.
Outcome measurement
The monitoring process was designed to encourage patient
compliance, allow computer-assisted data analyses, and
facilitate communication among participants, physicians,
and educators. An average of sequential day measurements
avoided 1-day measurement risk error. Daily outcome
monitoring enabled educators to learn of participant quan-
titative progress in the less stressful environment of their
homes without travel, illustrate the consequences of apply-
ing principles taught, evaluate compliance, assist partici-
pants to identify the early stage of ﬂares, and compile
study statistics.
This digital monitoring system gave participants
a numerical value as to when to treat a ﬂare. It removed
much of the guesswork out of the patient self-administration
of hydrocortisone and gave participants conﬁdence to initiate
treatment quickly with less hydrocortisone.
The outcome measurement method was validated dur-
ing the preceding double-blind clinical trial1 to be equiva-
lent to physician global assessment and number of tender
joints, the most accurate disease measurements of rheuma-
toid arthritis intensity.
The ultimate test
Self-administration if hydrocortisone symptom improvements
observed during this study approximately doubled that of
standard treatments. Patient self-administration of hydrocorti-
sone achieved an average symptom improvement of 76% for
the 38 hydrocortisone-responding disorders of the study with
a narrow sigma value of 6% for those disorders where n>50,
see Table 3.
The 601 participants of this study with ﬁbromyalgia
averaged 77% symptom improvement whereas ﬁbromyal-
gia patients treated by milnacipran achieved 35–42%
symptom improvement; by pregabalin, 26–31%; and by
duloxetine, 17–30%.
The 579 with osteoarthritis of this study averaged 77%
symptom improvement whereas osteoarthritis patients
Irwin et al Dovepress
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treated by celecoxib achieved an estimated 25% symptom
improvement.
The 246 with rheumatoid arthritis of this study aver-
aged 78% symptom improvement whereas rheumatoid
arthritis patients treated by adalimumab achieved
41–61% symptom improvement; by etanercept, 8–51%;
and by inﬂiximab 23–47%.
The 51 with Parkinson’s disease of this study averaged
62% symptom improvement whereas Parkinson’s disease
patients treated with levodopa achieved 7–29% symptom
improvement. Parkinson’s disease dementia improved by
67% whereas levodopa exhibited no effect on dementia.
The 19 with multiple sclerosis of this study averaged
67% symptom improvement whereas multiple sclerosis
patients treated with glatiramer acetate achieved 16%
symptom improvement.
No signiﬁcant hydrocortisone adverse effects were
observed. Participants averaged ingesting 12 mg hydrocorti-
sone per day during self-administration. This consumption
rate is less than the 15 mg hydrocortisone per day that gives
rise to hydrocortisone adverse effects in the most sensitive
adults.4 The adverse effects were weight gain, hypertension,
gastrointestinal symptoms, insomnia, muscle pain or spasms,
and hyperglycemia as reported to occur during the preceding
study employing an identical protocol.1
Salient features
Compatibility of the protocol of this study with other
medicines is inherent. All medicines are designed to be
compatible with hydrocortisone that is ever present in
the blood.
The increased vasopermeability of inﬂammation8
allows extra plasma and immune cells to enter inﬂaming
tissues from the pressurized blood system to cause swel-
ling and the immune response. The HPA axis hydrocorti-
sone surge re-establishes normal vasopermeability to
terminate inﬂammation.
Once the surge is weakened, the patients become
overly sensitive to all inﬂammation-initiating and exacer-
bating events.
Patient self-administration of hydrocortisone features
dosage ﬂexibility. Pharmacological and physiological
doses of hydrocortisone are mingled with hydrocortisone
holidays to provide the needed ﬂexibility to counteract the
dynamic exacerbation and remission character of chronic
inﬂammation.
The resistance of Parkinson’s disease, multiple
sclerosis, dementia, and ﬁbromyalgia to other treatments
and their positive responses to hormone hydrocortisone
treatment can be attributed to the responsible chronic
inﬂammation being located within the brain protected by
the blood-brain barrier.
Patient self-administration of hydrocortisone eliminates
most chronic pain by extinguishing chronic inﬂammation.
The efﬁcacies are similar to that of narcotic treatment but
without addiction and mental disturbance. With the per-
mission of the surgeon and anesthesiologist, one partici-
pant successfully used patient self-administration of
hydrocortisone as the only anesthetic to recover from
a knee replacement surgery.
The HPA axis has been reported dysfunctional in
certain circumstances.9–12 Reported consequences of
the dysfunction were brain-immune interactions, dis-
ease susceptibility, allergies, inﬂammatory/autoimmune
diseases, ﬁbromyalgia, rheumatoid arthritis, post-
traumatic stress syndrome, depression, burnout, chronic
fatigue syndrome, inﬂammatory bowel disease, multi-
ple sclerosis, attention deﬁcit hyperactivity disorder,
and alcoholism. These are consistent with the hydro-
cortisone treatment results for these disorders portrayed
in Table 3.
Chronic inﬂammation is probably the ﬁrst step on the
pathway to Addison’s disease. After the body production
of the hydrocortisone pulse fails to produce the extra
hydrocortisone required for the surge, the production of
hydrocortisone will likely deteriorate further to not being
able to maintain the normal homeostasis hydrocortisone
concentration in the blood.
Patient self-administration of hydrocortisone is FDA-
compliant for hydrocortisone use applied to corticosteroid-
responding disorders.
Bone and joint destruction are reduced during low-dose
administration of corticosteroids.13
Patients desire to take control of their disorder rather
than let it control their lives. They honor physicians who
will train and trust them to use hydrocortisone.
Conclusions
Patient self-administration of hydrocortisone safely
achieves superior symptom control for 38 hydrocortisone-
responding disorders at equal rates and efﬁcacies. These
results are consistent with the body having an inﬂamma-
tion control system and chronic inﬂammation being
a disorder unto itself with differing symptoms sets depen-
dent on its location.
Dovepress Irwin et al
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Informed consent
All participants signed a written informed consent form.
This study was performed as a research study planned
by an appointed committee from within the University
of North Dakota School of Medicine with the protocol
and informed consent form preapproved by the
Institutional Review Boards of the University of North
Dakota, North Dakota State University, and the Dakota
Medical Center.
Data Sharing
The computer deidentiﬁed participant data containing gra-
phic progress reports with total symptom scores and daily
hydrocortisone consumption vs time are in computer/elec-
tronic form and will be accessible from June l, 2019 to
August 31, 2019. The data are located at 2579 Movil Bay
Lane NE, Bemidji, MN 56601.
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